Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke (SPARCL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00147602|
Recruitment Status : Completed
First Posted : September 7, 2005
Last Update Posted : April 22, 2015
|Condition or disease||Intervention/treatment||Phase|
|Cardiovascular Disease||Drug: atorvastatin||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||4732 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Double-Blind, Randomized, Placebo- Controlled Study Of Atorvastatin As Prevention Of Cerebrovascular Events In Patients With A Previous Transient Ischemic Attack (TIA) Or Stroke|
|Study Start Date :||November 1998|
|Estimated Study Completion Date :||November 2005|
- Time to occurrence of fatal or non-fatal stroke
- Time to occurrence of an acute coronary event, consisting of cardiac death, nonfatal myocardial infarction, resuscitated cardiac arrest or unstable angina.
- Time to occurrence of a cerebrovascular event, defined as fatal or nonfatal stroke or TIA.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00147602
Show 130 Study Locations
|Study Director:||Pfizer CT.gov Call Center||Pfizer|